A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Stichting Hemato-Oncologie voor Volwassenen Nederland
Barbara Ann Karmanos Cancer Institute
University Hospital Southampton NHS Foundation Trust
Institute of Hematology & Blood Diseases Hospital, China
Peter MacCallum Cancer Centre, Australia
The First Hospital of Jilin University
University of Birmingham
Kosin University Gospel Hospital
Kosin University Gospel Hospital
University Hospital Southampton NHS Foundation Trust
University College, London
Arbeitsgemeinschaft medikamentoese Tumortherapie
Asan Medical Center